Regeneron Pharmaceuticals Profile

386.67
USD 4.95  1.3%
358.63Last Month High 387.54 
380.34Trading Day  High 389.82 

Acquisition by Christopher Fenimore of 12300 shares of Regeneron Pharmaceuticals subject to Rule 16b-3

Regeneron Pharmaceuticals Inc insider trading alert for grant of non-qualified stock option (right to buy) by Christopher Fenimore, VP Controller, on December 13, 2017. This event was filed by Regeneron Pharmaceuticals with SEC on 2017-12-13. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Regeneron Pharmaceuticals Summary

Regeneron Pharmaceuticals Inc (REGN) is traded on NASDAQ in USA. It is located in NEW YORK, U.S.A and employs 4,786 people. Regeneron Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Large-Cap' category with current market capitalization of 40.7 B. Regeneron Pharmaceuticals Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 104.98 M outstanding shares of which 2.13 M shares are at this time shorted by private and institutional investors with about 2.32 trading days to cover. REGENERON PHARMAC currently holds about 1.38 B in cash with 1.12 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.92.
Check Regeneron Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Fmr LlcCommon Shares7 M3.1 B
Capital World InvestorsCommon Shares6.6 M2.9 B
Susquehanna International Group LlpPut Options1.2 M542.1 M
Susquehanna International Group LlpCall Options972.7 K434.9 M
View Regeneron Pharmaceuticals Diagnostics

Selected Regeneron Pharmaceuticals Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Regeneron Pharmaceuticals Against Markets

Current Ratings  

Regeneron Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
< 1% 
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameRegeneron Pharmaceuticals Inc
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Pharmaceuticals And Biosciences
InstrumentUSA Stock Stocks Directory
RegionNorth America
LocationNEW YORK, U.S.A
Business Address777 Old Saw Mill River Road, Tarrytown, NY 10591-6707, United States
Foreign Associates
ExchangeNASDAQ
CIK Number00872589.0
ISINUS75886F1075
CUSIP75886F107
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.regeneron.com
Contact Number914 847 7000
CurrencyUSD - US Dollar

Recommendations

Regeneron Pharmaceuticals Analyst Recommendations
Target PriceAdvice# of Analysts
428.29Hold14Odds
Regeneron Pharmaceuticals Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Regeneron Pharmaceuticals Analyst Advice  

Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Earnings

Regeneron Pharmaceuticals Earnings Estimates
EPSEstimate Date
Quarterly Estimate2.5May 4, 2017
Regeneron Pharmaceuticals Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate